化疗引起的周围神经病（CIPN）的生物学预测因子：MASCC 神经并发症工作组概述。
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
机构信息
National University of Singapore, Singapore, Singapore.
National Cancer Centre Singapore, Singapore, Singapore.
出版信息
Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30.
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
摘要
化疗引起的周围神经病（CIPN）是一种常见的、使人虚弱的疾病，与许多化疗药物有关。通常与 CIPN 发展有关的药物包括铂类药物、紫杉烷类、长春碱类生物碱、硼替佐米和沙利度胺类似物。由于个体之间的药物反应可能有所不同，因此有人假设个体的特定遗传变异可能会影响参与药物药代动力学、离子通道功能、神经毒性和 DNA 修复的基因的调节，从而影响 CIPN 的发展和严重程度。其他分子标记物的变异也可能影响 CIPN 的发生率和严重程度。因此，本综述的目的是总结已知的 CIPN 的生物学（分子和基因组）预测因子，并讨论促进该领域进展的方法。
相似文献
1
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30.
2
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
Bull Cancer. 2018 Nov;105(11):1020-1032. doi: 10.1016/j.bulcan.2018.07.009. Epub 2018 Sep 20.
3
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Support Care Cancer. 2015 Feb;23(2):513-24. doi: 10.1007/s00520-014-2408-8. Epub 2014 Sep 26.
4
Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.
Crit Rev Oncol Hematol. 2020 Jan;145:102831. doi: 10.1016/j.critrevonc.2019.102831. Epub 2019 Nov 13.
5
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S63-S73. doi: 10.1111/jns.12334.
6
Chemotherapy-induced neuropathy: A comprehensive survey.
Cancer Treat Rev. 2014 Aug;40(7):872-82. doi: 10.1016/j.ctrv.2014.04.004. Epub 2014 Apr 18.
7
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy.
Front Immunol. 2021 Feb 4;11:626687. doi: 10.3389/fimmu.2020.626687. eCollection 2020.
8
A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Support Care Cancer. 2017 Jan;25(1):195-204. doi: 10.1007/s00520-016-3404-y. Epub 2016 Sep 9.
9
Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
Clin J Oncol Nurs. 2007 Jun;11(3):361-76. doi: 10.1188/07.CJON.361-376.
10
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7.
引用本文的文献
1
Chemotherapy-Induced Peripheral Polyneuropathy in Pediatric Acute Lymphoblastic Leukemia: A Case Report on Manifestation, Management, and Outcome.
Cancer Rep (Hoboken). 2025 Aug;8(8):e70293. doi: 10.1002/cnr2.70293.
2
Clinical benefits of enhanced 3D-NEVERview sequence in MRI simulation for nasopharyngeal carcinoma patients received radiotherapy.
BMC Cancer. 2025 Jul 29;25(1):1232. doi: 10.1186/s12885-025-14695-8.
3
The Role of Microcirculatory Dysfunction During Paclitaxel Treatment as a Critical Co-Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy.
Geburtshilfe Frauenheilkd. 2025 Mar 17;85(7):710-723. doi: 10.1055/a-2499-9856. eCollection 2025 Jul.
4
Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study.
Support Care Cancer. 2025 Apr 8;33(5):362. doi: 10.1007/s00520-025-09392-y.
5
The Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients.
Basic Clin Pharmacol Toxicol. 2025 May;136(5):e70022. doi: 10.1111/bcpt.70022.
6
Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer.
Support Care Cancer. 2025 Mar 10;33(4):263. doi: 10.1007/s00520-025-09336-6.
7
KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats.
J Pharmacol Exp Ther. 2024 Oct 18;391(2):231-240. doi: 10.1124/jpet.124.002190.
8
Oral Problems in Oncology Patients Undergoing Chemotherapy for Solid Tumors: A Prospective Observational Study.
Cancers (Basel). 2023 Dec 29;16(1):176. doi: 10.3390/cancers16010176.
9
Neuropsychiatric complications and associated management in adolescent and young adult cancer survivors: An All of Us study.
Cancer Med. 2023 Nov;12(22):20953-20963. doi: 10.1002/cam4.6641. Epub 2023 Oct 30.
10
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship.
Nat Rev Clin Oncol. 2023 Aug;20(8):527-542. doi: 10.1038/s41571-023-00776-9. Epub 2023 May 25.
本文引用的文献
1
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7.
2
A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
Gynecol Oncol. 2019 Feb;152(2):310-315. doi: 10.1016/j.ygyno.2018.12.002. Epub 2018 Dec 14.
3
Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Pharmacogenet Genomics. 2018 Aug;28(8):189-195. doi: 10.1097/FPC.0000000000000345.
4
Using stratified medicine to understand, diagnose, and treat neuropathic pain.
Pain. 2018 Sep;159 Suppl 1(Suppl 1):S31-S42. doi: 10.1097/j.pain.0000000000001301.
5
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26.
6
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.
J Clin Invest. 2018 Feb 1;128(2):816-825. doi: 10.1172/JCI96160. Epub 2018 Jan 16.
7
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.
8
Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
J Cancer Surviv. 2018 Apr;12(2):234-245. doi: 10.1007/s11764-017-0662-8. Epub 2017 Nov 20.
9
Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer.
Sci Rep. 2017 Sep 18;7(1):11785. doi: 10.1038/s41598-017-08257-7.
10
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.
Front Mol Neurosci. 2017 May 31;10:174. doi: 10.3389/fnmol.2017.00174. eCollection 2017.
Zotero 插件